---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-001738"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2021-09-09T23:59:59+00:00"
generated_at: "2026-06-29T04:44:18.624202+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RxSight Q2 revenue $4.9M (+81% YoY); net loss $(13.5)M; raises ~$120M in July IPO

## Summary
- Revenue $4.9M (+81% YoY); sold 25 LDDs and 1,825 LALs during Q2.
- Net loss $(13.5)M ($(3.28)/share basic); adjusted net loss $(13.3)M ($(3.24)/share).
- Gross loss $(0.8)M due to $1.7M inventory reserve for updated LAL with ActivShield.
- Completed IPO in July 2021 raising ~$120M net proceeds; cash & equivalents $61.7M at June 30.
- FDA approval and launch of LAL with ActivShield technology; new VP of U.S. Sales appointed.

## SEC filing metadata
- accession: 0000950170-21-001738
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2021-09-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017021001738/0000950170-21-001738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017021001738/rxst-20210909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-001738
- JSON: https://secwatch.observer/filing/0000950170-21-001738.json
- Plain text: https://secwatch.observer/filing/0000950170-21-001738.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.